Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

Human Genome Sciences, Inc. today will announce its priority goals for 2010 and report on the Company’s increasing momentum toward commercialization of late-stage products for systemic lupus and chronic hepatitis C in a presentation by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 28th Annual JPMorgan Healthcare Conference in San Francisco.

12 Jan 2010

Proteus Biomedical signs worldwide license and collaboration agreement with Novartis

Proteus Biomedical Inc., a pioneer in intelligent medicine, entered into an exclusive worldwide license and collaboration agreement with Novartis to develop and commercialize pharmaceutical products that incorporate Proteus’ novel sensor-based technologies in the field of organ transplantation.

12 Jan 2010

University Hospitals in Cleveland selects Sectra as PACS provider

University Hospitals in Cleveland, Ohio has selected the IT and medical-technology company Sectra as their PACS provider. University Hospitals has been recognized by Thomson Reuters as a Top 10 hospital system in the U.S., and by U.S. News and World Report as one of America’s best hospitals.

12 Jan 2010

CEL-SCI completes validation of its GMP manufacturing facility

CEL-SCI Corporation, a late-stage oncology company and a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases, announced today it has completed the validation of all critical utilities and manufacturing equipment at its GMP manufacturing facility in Maryland.

12 Jan 2010

4SC commences treatment in its resminostat Phase II trial for HL

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today announced the treatment of the first patient in a Phase II study evaluating resminostat (4SC-201), an oral pan-histone-deacetylase (HDAC) inhibitor in relapsed or refractory Hodgkin's Lymphoma (HL) patients.

12 Jan 2010

Sage Bionetworks, Pfizer sign new research partnership to analyze advanced network models of cancer

Sage Bionetworks has announced today a new research partnership with Pfizer, Inc. to build, analyze and exploit advanced network models of cancer. Pfizer will provide research funding to Sage to analyze large, globally coherent datasets from Pfizer, Sage and the public domain.

12 Jan 2010

Multigene test results impact physicians and patients' decisions on breast cancer therapy

A 21-gene test that predicts whether early stage breast cancer patients will benefit from chemotherapy is having a big impact on treatment decisions by patients and doctors alike.

12 Jan 2010

Neoprobe submits IND amendment to FDA for RIGScan CR radiopharmaceutical

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, announced today that it has submitted an investigational new drug (IND) amendment to the United States Food and Drug Administration (FDA) which includes the design of a proposed Phase 3 clinical trial of Neoprobe’s RIGScan® CR radiopharmaceutical.

12 Jan 2010

Tampa Bay Partnership releases new briefs on the economic and business growth in the Tampa Bay Region

SRI International Dedicates New Tampa Bay Research Facility SRI International, one of the world's leading independent research and technology development organizations, officially opened its new 40,000-square-foot research facility located at the Port of St. Petersburg.

11 Jan 2010

Institut Curie, Ipsogen sign scientific collaboration agreement in breast cancer domain

The INSTITUT CURIE and IPSOGEN (FR0010626028 - ALIPS) announce the signing of a scientific collaboration agreement in the breast cancer domain. Within the framework of this project, the current scientific knowledge on Ipsogen's MapQuant Dx Grade Genomic, HER2 and HR tests will be increased thanks to new data established from a large population of patients treated at the Institut Curie.

11 Jan 2010

Mirna Therapeutics receives ETF award to develop miRNA therapeutics for multiple cancers

Mirna Therapeutics announced today that the Company received a $5 million award from the State of Texas through the Texas Emerging Technology Fund (“ETF”). The ETF was created with the goal of growing new and existing businesses to accelerate the introduction of new products and services in the marketplace. This is the largest award of this type that has ever been granted.

11 Jan 2010

EpiCept, Meda enter into exclusive commercialization agreement for Ceplene

EpiCept Corporation announced today that it has entered into an exclusive commercialization agreement for Ceplene® (histamine dihydrochloride) with Meda AB, a leading international specialty pharmaceutical company based in Stockholm. Ceplene is EpiCept’s novel therapy approved in the European Union with orphan drug status for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first remission.

11 Jan 2010

Quidel to acquire Diagnostic Hybrids for $130M

Quidel Corporation, a leading provider of rapid point-of-care diagnostic tests, announced today the signing of a definitive agreement to acquire privately held Diagnostic Hybrids, Inc. for approximately $130 million in cash.

10 Jan 2010

Selection of therapeutic workshops to be presented at the Twelfth Annual BIO CEO & Investor Conference

“This year’s BIO CEO & Investor Conference will provide a unique forum to showcase therapeutic areas with key catalysts – from new and dynamic therapies to cutting edge investment opportunities,” said Alan Eisenberg, executive vice president of Emerging Companies & Business Development at BIO.

9 Jan 2010

Home-laundered scrubs have greater bacterial contamination than other alternatives

A study comparing the aerobic bacterial bioburden associated with surgical scrub attire shows significantly greater contamination among home-laundered attire than scrubs laundered by the healthcare facility, scrubs sent out by the facility to a third-party company for laundering, or single-use/disposable scrubs.

9 Jan 2010

Results of EpiCept's Special Meeting of Stockholders announced

EpiCept Corporation announced today the results of its Special Meeting of Stockholders held on January 7, 2010 in Tarrytown, NY.

9 Jan 2010

Research determines and validates the efficacy of T category in IASLC's Staging Manual

Research released in the January 2010 issue of the Journal of Thoracic Oncology sought to determine and validate the efficacy of the recent reclassification of the T category in the IASLC's Staging Manual in Thoracic Oncology.

9 Jan 2010

Time frame for parents to begin toilet training lessons for children

Researchers at The Bristol-Myers Squibb Children's Hospital (BMSCH) at Robert Wood Johnson University Hospital (RWJUH) and UMDNJ-Robert Wood Johnson Medical School (UMDNJ-RWJMS) have completed a study that pinpoints the period between 24 and 32 months of age as most effective time frame for parents to begin toilet training lessons with their children.

9 Jan 2010

Biomarker may enable personalized GVHD treatment for bone marrow transplant patients

University of Michigan researchers have identified the first biomarker of graft-versus-host disease of the skin. The discovery makes possible a simple blood test that should solve a treatment dilemma facing doctors with patients who frequently develop rashes after bone marrow transplants.

9 Jan 2010

Plexxikon commences dosing in PLX4032 Phase 3 trial for metastatic melanoma

Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 “BRAF Inhibitor in Melanoma” (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.

9 Jan 2010

Oncology News and Research

Further Reading

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

Proteus Biomedical signs worldwide license and collaboration agreement with Novartis

University Hospitals in Cleveland selects Sectra as PACS provider

CEL-SCI completes validation of its GMP manufacturing facility

4SC commences treatment in its resminostat Phase II trial for HL

Sage Bionetworks, Pfizer sign new research partnership to analyze advanced network models of cancer

Multigene test results impact physicians and patients' decisions on breast cancer therapy

Neoprobe submits IND amendment to FDA for RIGScan CR radiopharmaceutical

Tampa Bay Partnership releases new briefs on the economic and business growth in the Tampa Bay Region

Institut Curie, Ipsogen sign scientific collaboration agreement in breast cancer domain

Mirna Therapeutics receives ETF award to develop miRNA therapeutics for multiple cancers

EpiCept, Meda enter into exclusive commercialization agreement for Ceplene

Quidel to acquire Diagnostic Hybrids for $130M

Selection of therapeutic workshops to be presented at the Twelfth Annual BIO CEO & Investor Conference

Home-laundered scrubs have greater bacterial contamination than other alternatives

Results of EpiCept's Special Meeting of Stockholders announced

Research determines and validates the efficacy of T category in IASLC's Staging Manual

Time frame for parents to begin toilet training lessons for children

Biomarker may enable personalized GVHD treatment for bone marrow transplant patients

Plexxikon commences dosing in PLX4032 Phase 3 trial for metastatic melanoma

Cancer Research eBook

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News